In future studies, it will be interesting to (1) perform in vivo experiments using NAFLD animal models to evaluate the long-term effects of isoquercitrin on hepatic lipid metabolism and (2) explore additional molecular mechanisms—such as potential crosstalk with mTOR and YAP signaling pathways—that may further explain the cytoprotective properties of isoquercitrin. Here, MTOR is linked to metabolic dysfunction-associated steatotic liver disease.